C12N 2760/16034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/16034 (Use of virus or viral component as vaccine) appears on 315 US grants and 531 published applications in this corpus.
Search patents in C12N- Granted patents
- 315
- Published applications
- 531
- Assignees
- 276
- Inventors
- 929
- Latest grant
- 30 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 3 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 2 | 1 |
| 2003 | 0 | 3 |
| 2004 | 1 | 17 |
| 2005 | 3 | 9 |
| 2006 | 1 | 2 |
| 2007 | 5 | 5 |
| 2008 | 3 | 7 |
| 2009 | 0 | 18 |
| 2010 | 4 | 28 |
| 2011 | 3 | 19 |
| 2012 | 6 | 19 |
| 2013 | 9 | 26 |
| 2014 | 17 | 29 |
| 2015 | 26 | 49 |
| 2016 | 24 | 57 |
| 2017 | 24 | 43 |
| 2018 | 34 | 34 |
| 2019 | 33 | 35 |
| 2020 | 30 | 24 |
| 2021 | 20 | 27 |
| 2022 | 21 | 20 |
| 2023 | 10 | 12 |
| 2024 | 11 | 25 |
| 2025 | 14 | 9 |
| 2026 | 4 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- MDCK suspension cell lines in serum-free, chemically-defined media for vaccine production30 Jun 2026US 12,667,612 B2Fujifilm Biosciences Inc.
- Modified virus-like particles of CMV21 Apr 2026US 12,605,454 B2Saiba GmbH
- Multivalent HVT vector vaccine31 Mar 2026US 12,589,147 B2Intervet Inc.
- Methods of generating broadly protective vaccine compositions comprising neuraminidase13 Jan 2026US 12,521,430 B2Sanofi Pasteur Limited
- Influenza mRNA vaccines30 Dec 2025US 12,508,308 B2CureVac AG
- Differential coating of microprojections and microneedles on arrays8 Oct 2026US 2026/0306611 A1Vaxxas Pty Limited
- Improved alum-anchored immunogens1 Oct 2026US 2026/0295039 A1Massachusetts Institute of Technology
- Modified virus-like particles of cmv10 Sep 2026US 2026/0263612 A1Saiba GmbH
- Influenza mrna vaccines20 Aug 2026US 2026/0240980 A1CureVac AG
- Influenza neuraminidase tetramers13 Aug 2026US 2026/0234589 A1Icosavax, Inc.
Most cited
By later US patents
- Frozen piercing implements and methods for piercing a substrate284US 8,784,385 B2The Invention Science Fund I, LLC · 2014
- GITR-binding antibodies141US 7,812,135 B2TolerRx, Inc. · 2010
- Methods for inducing or enhancing an immune response by administering agonistic GITR-binding antibodies121US 8,388,967 B2GITR, Inc. · 2013
- Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response111US 5,830,702 AThe Trustees of the University of Pennsylvania · 1998
- Method for treating allergic lung disease110US 5,849,719 AThe Regents of the University of California · 1998